Pasithea Therapeutics Corp. Share Price
KTTAPasithea Therapeutics Corp. Stock Performance
Open $0.45 | Prev. Close $0.47 | Circuit Range N/A |
Day Range $0.45 - $0.47 | Year Range $0.29 - $2.06 | Volume 11,370 |
Average Traded $0.47 |
Pasithea Therapeutics Corp. Share Price Chart
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Pasithea Therapeutics Corp. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
21-Jul-26 | $0.45 | $0.46 | +0.00% |
21-Jul-26 | $0.45 | $0.46 | -3.18% |
20-Jul-26 | $0.49 | $0.47 | +4.89% |
17-Jul-26 | $0.46 | $0.45 | -2.39% |
16-Jul-26 | $0.45 | $0.46 | -4.36% |
15-Jul-26 | $0.48 | $0.48 | -3.02% |
14-Jul-26 | $0.48 | $0.50 | +10.44% |